3.07 USD
+0.29 (+10.43%)
3.16 USD
+0.09 (+2.93%)
Taking everything into account, MEIP scores 4 out of 10 in our fundamental rating. MEIP was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MEIP as it has an excellent financial health rating, but there are worries on the profitability. MEIP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year MEIP was profitable.
- In the past year MEIP has reported a negative cash flow from operations.
- In the past 5 years MEIP reported 4 times negative net income.
- In the past 5 years MEIP reported 4 times negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -152.38%, MEIP is doing worse than 85.95% of the companies in the same industry.
- MEIP has a worse Return On Equity (-162.03%) than 63.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| ROIC | N/A |
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MEIP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MEIP has less shares outstanding
- MEIP has more shares outstanding than it did 5 years ago.
- MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 19.34 indicates that MEIP is not in any danger for bankruptcy at the moment.
- MEIP has a Altman-Z score of 19.34. This is amongst the best in the industry. MEIP outperforms 92.05% of its industry peers.
- MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 19.34 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
- MEIP has a Current Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 16.78, MEIP belongs to the best of the industry, outperforming 92.05% of the companies in the same industry.
- MEIP has a Quick Ratio of 16.78. This indicates that MEIP is financially healthy and has no problem in meeting its short term obligations.
- MEIP's Quick ratio of 16.78 is amongst the best of the industry. MEIP outperforms 92.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.78 | ||
| Quick Ratio | 16.78 |
3. Growth
3.1 Past
- MEIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.67%, which is quite impressive.
- Looking at the last year, MEIP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
- The Revenue has been growing by 67.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -67.16% on average over the next years. This is quite bad
- The Revenue is expected to grow by 85.04% on average over the next years. This is a very strong growth
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 1.15, the valuation of MEIP can be described as very cheap.
- 99.45% of the companies in the same industry are more expensive than MEIP, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of MEIP to the average of the S&P500 Index (27.30), we can say MEIP is valued rather cheaply.
- MEIP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.15 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as MEIP's earnings are expected to decrease with -37.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
5. Dividend
5.1 Amount
- MEIP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEI PHARMA INC / MEIP FAQ
What is the fundamental rating for MEIP stock?
ChartMill assigns a fundamental rating of 4 / 10 to MEIP.
Can you provide the valuation status for MEI PHARMA INC?
ChartMill assigns a valuation rating of 2 / 10 to MEI PHARMA INC (MEIP). This can be considered as Overvalued.
What is the profitability of MEIP stock?
MEI PHARMA INC (MEIP) has a profitability rating of 0 / 10.
Can you provide the PE and PB ratios for MEIP stock?
The Price/Earnings (PE) ratio for MEI PHARMA INC (MEIP) is 1.15 and the Price/Book (PB) ratio is 5.16.
Can you provide the dividend sustainability for MEIP stock?
The dividend rating of MEI PHARMA INC (MEIP) is 0 / 10 and the dividend payout ratio is 0%.